Trial Profile
Dose-Response in Radioimmunotherapy of Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Iodine-131 tositumomab (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Feb 2007 New trial record.